{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:12:36Z","timestamp":1793103156893,"version":"4.5.0"},"reference-count":42,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Vector-Borne and Zoonotic Diseases"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Lyme borreliosis (LB) is the most common tick-borne disease in Europe. To inform European intervention strategies, including vaccines under development, we conducted a systematic review for LB incidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We searched publicly available surveillance data reporting LB incidence in Europe from 2005 to 2020. Population-based incidence was calculated as the number of reported LB cases per 100,000 population per year (PPY), and high LB risk areas (incidence &gt;10\/100,00 PPY for 3 consecutive years) were estimated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Estimates of LB incidence were available for 25 countries. There was marked heterogeneity in surveillance systems (passive vs. mandatory and sentinel sites vs. national), case definitions (clinical, laboratory, or both), and testing methods, limiting comparison across countries. Twenty-one countries (84%) had passive surveillance; four (Belgium, France, Germany, and Switzerland) used sentinel surveillance systems. Only four countries (Bulgaria, France, Poland, and Romania) used standardized case definitions recommended by European public health institutions. Among all surveillance systems and considering any case definition for the most recently available years, national LB incidences were highest in Estonia, Lithuania, Slovenia, and Switzerland (&gt;100 cases\/100,000 PPY), followed by France and Poland (40\u201380\/100,000 PPY), and Finland and Latvia (20\u201340\/100,000 PPY). Incidences were lowest in Belgium, Bulgaria, Croatia, England, Hungary, Ireland, Norway, Portugal, Romania, Russia, Scotland, and Serbia (&lt;20\/100,000 PPY). At the subnational level, highest LB incidences (&gt;100\/100,000 PPY) were observed in areas of Belgium, Czech Republic, France, Germany, and Poland. Overall, on average 128,888 cases are reported annually. An estimated 202\/844 million (24%) persons in Europe reside in areas of high LB incidence and 202\/469 million (43.2%) persons reside in areas of high LB incidence among countries with surveillance data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our review showed substantial variability in reported LB incidence across and within European countries, with highest incidences reported from the Eastern, Northern (Baltic states and Nordic countries), and Western Europe surveillance systems. Standardization of surveillance systems, including wider implementation of common case definitions, is urgently needed to interpret the range of differences in LB incidence observed across European countries.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/vbz.2022.0071","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T11:44:14Z","timestamp":1681818254000},"page":"156-171","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":97,"title":["Incidence of Lyme Borreliosis in Europe from National Surveillance Systems (2005\u20132020)"],"prefix":"10.1177","volume":"23","author":[{"given":"Leah","family":"Burn","sequence":"first","affiliation":[{"name":"P95 Pharmacovigilance &amp; Epidemiology, Princeton, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao Mai Phuong","family":"Tran","sequence":"additional","affiliation":[{"name":"P95 Pharmacovigilance &amp; Epidemiology, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pilz","sequence":"additional","affiliation":[{"name":"Pfizer Global Medical Affairs, Vaccines, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Vyse","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines Medical, Walton Oaks, Surrey, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Fletcher","sequence":"additional","affiliation":[{"name":"Pfizer Emerging Markets Medical Affairs, Vaccines, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick J.","family":"Angulo","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines Medical Development, Scientific and Clinical Affairs, Collegeville, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford D.","family":"Gessner","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines Medical Development, Scientific and Clinical Affairs, Collegeville, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer C.","family":"Mo\u00efsi","sequence":"additional","affiliation":[{"name":"Pfizer Medical Development, Scientific and Clinical Affairs, Vaccines, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Jodar","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines Medical Development, Scientific and Clinical Affairs, Collegeville, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Stark","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines Medical Development, Scientific and Clinical Affairs, Collegeville, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-9-79"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-13669-w"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13690-015-0079-7"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.666554"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00018-19"},{"key":"e_1_3_6_7_1","first-page":"1","article-title":"Case definitions for infectious conditions under public health surveillance","volume":"46","author":"Centers for Disease Control and Prevention","year":"1997","unstructured":"Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. MMWR Recomm Rep, 1997; 46:1\u201355.","journal-title":"MMWR Recomm Rep"},{"key":"e_1_3_6_8_1","unstructured":"Centers for Disease Control and Prevention. Lyme Disease (Borrelia burgdorferi) 2017 Case Definition. 2021a. Available from: https:\/\/ndc.services.cdc.gov\/case-definitions\/lyme-disease-2017 [Last accessed: November 16 2022]."},{"key":"e_1_3_6_9_1","unstructured":"Centers for Disease Control and Prevention. Lyme Disease Maps: Most Recent Year. 2021b. Available from: https:\/\/www.cdc.gov\/lyme\/datasurveillance\/maps-recent.html [Last accessed: June 6 2022]."},{"key":"e_1_3_6_10_1","unstructured":"Centers for Disease Control and Prevention. Lyme Disease (Borrelia burgdorferi) 2022 Case Definition. 2022a. Available from: https:\/\/ndc.services.cdc.gov\/case-definitions\/lyme-disease-2022 [Last accessed: November 16 2022]."},{"key":"e_1_3_6_11_1","unstructured":"Centers for Disease Control and Prevention. Lyme Surveillance. 2022b. Available from: https:\/\/www.cdc.gov\/lyme\/datasurveillance\/index.html [Last accessed: November 16 2022]."},{"key":"e_1_3_6_12_1","unstructured":"Dicker RC Coronade F Koo D Parrish IRG. U.S. Department of Health and Human Services: CDC. Lesson three: measures of risk. In Principles of Epidemiology in Public Health Practice: An Introduction to Applied Epidemiology and Biostatistics. Atlanta GA; 2012. Available from: https:\/\/www.cdc.gov\/csels\/dsepd\/ss1978\/SS1978.pdf [Last accessed: June 15 2022]."},{"key":"e_1_3_6_13_1","unstructured":"European Centre for Disease Prevention and Control. 2020. Available from: https:\/\/www.ecdc.europa.eu\/en [Last accessed: November 20 2020]."},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy510"},{"key":"e_1_3_6_15_1","unstructured":"European Center for Disease Prevention and Control. European Center for Disease Prevention and Control. ECDC Comment: European Commission Updates Communicable Disease Surveillance List\u2014Lyme Neuroborreliosis Now Under EU\/EEA Surveillance. 2018. Available from: https:\/\/www.ecdc.europa.eu\/en\/news-events\/ecdc-comment-european-commission-updates-communicable-disease-surveillance-list-lyme [Last accessed: June 15 2021]."},{"key":"e_1_3_6_16_1","unstructured":"European Commission. European Commission Implementing Decision (EU) 2018\/945 of 22 June 2018 on the Communicable Diseases and Related Special Health Issues to Be Covered by Epidemiological Surveillance as Well as Relevant Case Definitions 2018. Available from: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX%3A32018D0945 [Last accessed: July 25 2022]."},{"key":"e_1_3_6_17_1","unstructured":"Eurostat. Regional Statistics by NUTS Classification: Population and Area. 2022. Available from: https:\/\/ec.europa.eu\/eurostat\/databrowser\/explore\/all\/general?lang=en&subtheme=reg.reg_dem.reg_dempoar&display=list&sort=category [Last accessed: November 15 2022]."},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11060789"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A1579"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/20477724.2019.1598127"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00601-18"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2015.121"},{"key":"e_1_3_6_23_1","unstructured":"Lindgren E Jaenson TGT. Lyme Borreliosis in Europe: Influences of Climate and Climate Change Epidemiology Ecology and adaptation measures. WHO Regional Office for Europe: Denmark; 2006. Available from: https:\/\/www.euro.who.int\/__data\/assets\/pdf_file\/0006\/96819\/E89522.pdf [Last accessed: July 19 2022]."},{"key":"e_1_3_6_24_1","doi-asserted-by":"crossref","unstructured":"Nagarajan A Skufca J Vyse A et al. The landscape of Lyme borreliosis surveillance in Europe. Vector Borne Zoonotic Dis 2022 (In press).","DOI":"10.1089\/vbz.2022.0067"},{"key":"e_1_3_6_25_1","unstructured":"NHS Digital. Terminology and Classifications: Read Codes. 2022. Available from: https:\/\/digital.nhs.uk\/services\/terminology-and-classifications\/read-codes [Last accessed: November 15 2022]."},{"key":"e_1_3_6_26_1","unstructured":"PROSPERO. International Prospective Register of Systematic Reviews. Available from: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=236906 [Last accessed: November 16 2022]."},{"key":"e_1_3_6_27_1","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna Austria; 2016. Available from: https:\/\/www.R-project.org [Last accessed: November 23 2021]."},{"key":"e_1_3_6_28_1","unstructured":"R\u00e9seau Sentinelles. Lyme Disease. 2021. Available from: https:\/\/www.sentiweb.fr\/france\/fr\/?page=maladies&mal=18 [Last accessed: July 19 2022]."},{"key":"e_1_3_6_29_1","unstructured":"Robert Koch Institute . Robert Koch Institute. Survstat@RKI 2.0 General Information. 2021a. Available from: https:\/\/survstat.rki.de\/Content\/Query\/Create.aspx [Last accessed: May 31 2022]."},{"key":"e_1_3_6_30_1","unstructured":"Robert Koch Institute. Robert Koch Institute. Survstat@RKI 2.0 General Information. 2021b. Available from: https:\/\/survstat.rki.de\/Content\/Instruction\/Content.aspx#merkm [Last accessed: November 24 2021]."},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1558\/5\/mmwr.ss6622a1"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2010.03175.x"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.90"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.2110\/1\/cejph.a3937"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/fdw017"},{"key":"e_1_3_6_36_1","first-page":"413","article-title":"Study on Lyme borreliosis and six other tick-borne diseases, Franche-Comt\u00e9, 2010\u20132012","volume":"19","author":"Tessier S","year":"2018","unstructured":"Tessier S, , Yann LS, , Serre A, et al. Study on Lyme borreliosis and six other tick-borne diseases, Franche-Comt\u00e9, 2010\u20132012. Bull Epid\u00e9miol Hebd, 2018; 19\u201320:413\u2013418.","journal-title":"Bull Epid\u00e9miol Hebd"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31738-0"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1586\/eri.10.15"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2017.22.27.30569"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/17843286.2019.1694293"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780131009"},{"key":"e_1_3_6_42_1","unstructured":"World Health Organization. WHO Report on Global Surveillance of Epidemic-Prone Infectious Diseases. World Health Organization; 2000."},{"key":"e_1_3_6_43_1","unstructured":"World Health Organization. Annex: Regional Classifications. 2022. Available from: https:\/\/www.who.int\/observatories\/global-observatory-on-health-research-and-development\/classifications-and-standards\/country-groupings [Last accessed: February 6 2023]."}],"container-title":["Vector-Borne and Zoonotic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/vbz.2022.0071","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/vbz.2022.0071","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/vbz.2022.0071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:02:18Z","timestamp":1777590138000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/vbz.2022.0071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1089\/vbz.2022.0071"],"URL":"https:\/\/doi.org\/10.1089\/vbz.2022.0071","relation":{},"ISSN":["1530-3667","1557-7759"],"issn-type":[{"value":"1530-3667","type":"print"},{"value":"1557-7759","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]}}}